Pathophysiologic biomarkers for chronic spontaneous urticaria (CSU) are emerging, which can help better target therapies for ...
The most pronounced increase in pathology tests is seen among children aged 6-11 years, where allergy testing volumes grew ...
Objective This study aimed to explore health professionals’ perspectives on the management of preschool wheeze, including ...
Depemokimab-ulaa (Exdensur) has been approved by the US FDA as add-on maintenance therapy for severe asthma with an ...
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Exdensur ...
In this video, Jonathan A. Bernstein, MD, discusses findings about chronic itch presented at the American College of Allergy, ...
REX-8756 is a potent and selective oral STAT6 inhibitor that has shown complete 100% pathway inhibition and potent efficacy in preclinical models ...
ABSTRACT: Background: Carbocysteine is a mucoregulatory agent with anti-inflammatory properties used in chronic respiratory and otorhinolaryngological diseases. However, clinical evidence across ...
Asthma is a chronic inflammatory condition marked by an imbalance in the immune response within the airways. According to Lancet, asthma affects around 339 million people globally. While conventional ...
The atopic triad—eczema, asthma, and allergies—frequently presents early in pediatric patients and often shares overlapping immune dysfunction and environmental triggers. In this clinical review, Dr.
SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback